Cargando…

Is Chelation Therapy a Potential Treatment for Parkinson’s Disease?

Iron loading in some brain regions occurs in Parkinson’s Disease (PD), and it has been considered that its removal by iron chelators could be an appropriate therapeutic approach. Since neuroinflammation with microgliosis is also a common feature of PD, it is possible that iron is sequestered within...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ward, Roberta J., Dexter, David T., Martin-Bastida, Antonio, Crichton, Robert R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036775/ https://www.ncbi.nlm.nih.gov/pubmed/33805195 http://dx.doi.org/10.3390/ijms22073338

Ejemplares similares

Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease
por: Martin-Bastida, Antonio, et al.
Publicado: (2017)

The Efficacy of Iron Chelators for Removing Iron from Specific Brain Regions and the Pituitary—Ironing out the Brain
por: Crichton, Robert R., et al.
Publicado: (2019)

Iron, Neuroinflammation and Neurodegeneration
por: Ward, Roberta J., et al.
Publicado: (2022)

Chelators in the Treatment of Iron Accumulation in Parkinson's Disease
por: Mounsey, Ross B., et al.
Publicado: (2012)

New perspectives in iron chelation therapy for the treatment of Parkinson’s disease
por: Nuñez, Marco T., et al.
Publicado: (2019)

Benefits of Iron Chelators in the Treatment of Parkinson’s Disease
por: Zeng, Xiaoyan, et al.
Publicado: (2021)

Potential Treatment of Retinal Diseases with Iron Chelators
por: Shu, Wanting, et al.
Publicado: (2018)

Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease
por: Grolez, Guillaume, et al.
Publicado: (2015)

Antioxidant and Metal Chelation-Based Therapies in the Treatment of Prion Disease
por: Brazier, Marcus W., et al.
Publicado: (2014)

EDTA Chelation Therapy for the Treatment of Neurotoxicity
por: Fulgenzi, Alessandro, et al.
Publicado: (2019)

New Perspectives in Iron Chelation Therapy for the Treatment of Neurodegenerative Diseases
por: Nuñez, Marco T., et al.
Publicado: (2018)

Unscrambling the Role of Redox-Active Biometals in Dopaminergic Neuronal Death and Promising Metal Chelation-Based Therapy for Parkinson’s Disease
por: Gonzalez-Alcocer, Alfredo, et al.
Publicado: (2023)

EDTA Chelation Therapy in the Treatment of Neurodegenerative Diseases: An Update
por: Fulgenzi, Alessandro, et al.
Publicado: (2020)

Chelation therapy in liver diseases of childhood: Current status and response
por: Seetharaman, Jayendra, et al.
Publicado: (2021)

Evaluation of the potential role of chelation therapy in treatment of low to moderate lead exposures.
por: Chisolm, J J
Publicado: (1990)

Therapeutic Potential of Iron Chelating Therapy: Modification of Disease by Iron Depletion
por: Hershko, Chaim, et al.
Publicado: (1994)

Iron Chelation Therapy in Thalassemia Syndromes
por: Cianciulli, Paolo
Publicado: (2009)

Iron Chelation Therapy in Myelodysplastic Syndromes
por: Messa, Emanuela, et al.
Publicado: (2010)

Myelodysplastic Syndromes and Iron Chelation Therapy
por: Angelucci, Emanuele, et al.
Publicado: (2017)

Metal Chelation Therapy and Parkinson’s Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs
por: Tosato, Marianna, et al.
Publicado: (2019)

Combination Therapy Using Chelating Agent and Zinc for Wilson’s Disease
por: Chen, Jui-Chi, et al.
Publicado: (2015)

Current Biomedical Use of Copper Chelation Therapy
por: Baldari, Silvia, et al.
Publicado: (2020)

Chelation Therapy in Patients With Cardiovascular Disease: A Systematic Review
por: Ravalli, Filippo, et al.
Publicado: (2022)

Iron Chelators in Treatment of Iron Overload
por: Entezari, Sarina, et al.
Publicado: (2022)

Current surgical treatments for Parkinson's disease and potential therapeutic targets
por: Lee, Darrin J., et al.
Publicado: (2018)

Infusion Therapies in the Treatment of Parkinson’s Disease
por: van Laar, Teus, et al.
Publicado: (2023)

Chelation in Metal Intoxication
por: Flora, Swaran J.S., et al.
Publicado: (2010)

Current Treatments and New, Tentative Therapies for Parkinson’s Disease
por: Pardo-Moreno, Teresa, et al.
Publicado: (2023)

Chelation therapy after the Trial to Assess Chelation Therapy: results of a unique trial
por: Avila, Maria D., et al.
Publicado: (2014)

Hypopituitarism in Wilson’s disease resolved after copper-chelating therapy
por: Dauth, Nina, et al.
Publicado: (2021)

Chalcones as Potential Ligands for the Treatment of Parkinson’s Disease
por: Królicka, Ewelina, et al.
Publicado: (2022)

Recent Developments in Metal-Based Drugs and Chelating Agents for Neurodegenerative Diseases Treatments
por: Sales, Thais A., et al.
Publicado: (2019)

Potential cellular and regenerative approaches for the treatment of Parkinson’s disease
por: Lane, Emma L, et al.
Publicado: (2008)

Thalassemia Intermedia: Chelator or Not?
por: Lee, Yen-Chien, et al.
Publicado: (2022)

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2017)

Imaging Cognitive Impairment and Impulse Control Disorders in Parkinson's Disease
por: Martín-Bastida, Antonio, et al.
Publicado: (2021)

Iron Overload and Breast Cancer: Iron Chelation as a Potential Therapeutic Approach
por: Islam, Sufia, et al.
Publicado: (2022)

Iron Chelation as a Potential Therapeutic Approach in Acute Lung Injury
por: Zhang, Xiyang, et al.
Publicado: (2023)

EDTA chelation therapy for cardiovascular disease: a systematic review
por: Seely, Dugald MR, et al.
Publicado: (2005)

The Effect of Chelation Therapy on the Amino Aciduria and Peptiduria of Wilson's Disease
por: Asatoor, A. M., et al.
Publicado: (1983)

Cannot write session to /tmp/vufind_sessions/sess_0kbbqt8f922fboth1vmgvedc4t